Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Net Tangible Assets

The Net Tangible Assets of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 30, 2026 is 985.70 M CNY. In the previous year, Net Tangible Assets was 946.27 M CNY — a change of 4.17% (higher).

Net Tangible Assets

985.70 MCNY

YoY

4.17%

Last updated:

Net Tangible Assets of Shenzhen Neptunus Bioengineering Co is 2025 985.70 M CNY. Net Tangible Assets of Shenzhen Neptunus Bioengineering Co was 2024 946.27 M CNY. It decreases by 4.17% higher compared to the previous year.

The Shenzhen Neptunus Bioengineering Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
1.72 B CNY
Jan 1, 2019
2.53 B CNY
Jan 1, 2020
3.01 B CNY
Jan 1, 2021
2.96 B CNY
Jan 1, 2022
2.43 B CNY
Jan 1, 2023
1.67 B CNY
Jan 1, 2024
946.27 M CNY
Jan 1, 2025
985.70 M CNY
The Shenzhen Neptunus Bioengineering Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
985.70 MCNY+4.17%
946.27 MCNY-43.25%
1.67 BCNY-31.29%
2.43 BCNY-18.04%
2.96 BCNY-1.46%
3.01 BCNY+18.83%
2.53 BCNY+47.03%
1.72 BCNY+9.65%
1.57 BCNY-65.32%
4.52 BCNY+230.47%
1.37 BCNY+26.33%
1.08 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

Net Tangible Assets of Shenzhen Neptunus Bioengineering Co is 985.70 M CNY in 2025.

Net Tangible Assets of Shenzhen Neptunus Bioengineering Co changed from 946.27 M CNY to 985.70 M CNY, representing a 4.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Shenzhen Neptunus Bioengineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Shenzhen Neptunus Bioengineering Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Shenzhen Neptunus Bioengineering Co